Actinium's Abstracts on Antibody Radiation Conjugates and Novel Linker Tech Accepted for 2024 SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc., a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, has announced the acceptance of five abstracts for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. This event is scheduled to take place from June 8 to June 11, 2024, in Toronto, Canada. The accepted abstracts will highlight significant advancements in the treatment of high-risk acute myeloid leukemia (AML) using the company's targeted radiotherapies, Iomab-B and Actimab-A.

Iomab-B, a CD45 targeting ARC with an Iodine-131 payload, is being developed for conditioning patients for bone marrow transplants (BMT). Data from the Phase 3 SIERRA trial, which will be presented at the meeting, demonstrate its potential for preparing patients for potentially curative transplants. Actimab-A, on the other hand, targets CD33 with an Actinium-225 payload and is being tested in combination with the chemotherapy regimen CLAG-M in a Phase 1b trial. Both therapies have shown improved survival rates in patients with high-risk AML, including those with the TP53 mutation and those who have undergone prior venetoclax treatment.

In addition to its focus on blood cancers, Actinium will present an abstract detailing its novel linker technology, which enhances the delivery of targeted radiotherapy to solid tumors. This technology represents a significant expansion of Actinium's Antibody Radiation Conjugate pipeline, moving beyond hematologic malignancies to potentially treat a wider range of cancers.

Actinium’s Chairman and CEO, Sandesh Seth, emphasized the company’s commitment to advancing targeted radiotherapy. He highlighted the presentations at SNMMI as evidence of Actinium's leadership in this field and the promising potential of their therapies to treat challenging cases of relapsed and refractory AML. These therapies are particularly noteworthy for their ability to overcome genetic mutations and the effects of extensive prior treatments.

The detailed presentations at the SNMMI Annual Meeting will cover various aspects of Actinium’s research and development efforts, including:

1. Safety and Dosimetric Analysis of Lintuzumab-Ac225: This presentation will focus on the combination of Lintuzumab-Ac225 with intensive CLAG-M chemotherapy in patients with relapsed/refractory AML.

2. Bone Marrow Dosimetry from the SIERRA Trial: An exploratory analysis from the Phase 3 SIERRA trial of Iomab-B, focusing on bone marrow dosimetry and its implications for hematopoietic cell transplantation (HCT) in relapsed/refractory AML patients.

3. Survival Outcomes and Dosimetric Analysis of Iomab-B: This presentation will provide insights into the survival outcomes of patients with TP53 mutated relapsed/refractory AML following treatment with Iomab-B and subsequent allogeneic HCT.

4. Mathematical Modeling of Exposure Measurements: An analysis from the large multicenter Phase III SIERRA trial, focusing on mathematical modeling of exposure measurements following high-dose targeted therapy using 131I-apamistamab.

5. Evaluation of Novel DOTA-based Linkers: This will highlight the development and assessment of new DOTA-based linkers for improved targeted radiotherapy delivery to solid tumors.

The SNMMI Annual Meeting is a premier event in nuclear medicine and molecular imaging, providing a platform for professionals in the field to explore the latest research, technologies, and clinical applications. Actinium Pharmaceuticals aims to leverage this platform to showcase their innovations in targeted radiotherapy, which hold promise for significantly improving patient outcomes in both blood cancers and solid tumors.

Actinium continues to advance its pipeline with an emphasis on improving survival outcomes for patients who have not responded to existing therapies. The company holds over 230 patents and patent applications, including several related to the manufacture of the isotope Ac-225 in a cyclotron, reinforcing its position as a leader in targeted radiotherapy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!